The HD21 trial shows BrECADD offers superior gonadal function recovery and higher parenthood rates, especially in men, compared with eBEACOPP for advanced-stage classic Hodgkin lymphoma, supporting BrECADD as the preferred first-line therapy for fertility preservation.